Buparlisib治疗难治性滤泡型及低分化甲状腺癌的Ⅱ期研究
6个月无进展生存(PFS)概率为41.7%,低于预设的50%无效假设,未达主要终点;3-4级不良事件发生率为63%。
要点
- 6个月PFS概率41.7%,低于50%的预设阈值,主要终点未达到。
- 3-4级不良事件见于63%患者,以肝炎、高血糖、情绪障碍和皮肤毒性为主。
- 治疗期间平均肿瘤生长速率由3.78 mm/月降至0.8 mm/月(p<0.02)。
核心结论
- buparlisib在晚期放射性碘难治性FTC和PDTC中未显示显著疗效,6个月PFS概率低于预设的50%阈值。
- 肿瘤生长速率下降提示可能存在致癌通路的不完全抑制和/或逃逸机制,值得评估PI3K与MAPK通路抑制剂的联合治疗。
研究设计与样本
- 开放标签、多中心、Ⅱ期先导研究,主要终点为6个月无进展生存(PFS)概率。
- 给药方案为buparlisib 100 mg每日口服,对象为转移性、放射性碘难治、进展期患者。
主要发现
- 组织学为PDTC者25例(58%)、FTC者17例(40%)、Hürthle细胞癌1例(2%)。
- 可检测肿瘤中RAS突变占44%(12/27),PI3K通路激活占35%(8/23)。
- 6个月PFS概率41.7%(95%CI 7.7-55.5),12个月为20.9%(95%CI 0-35.7)。
- 6个月时25.6%患者疾病稳定、48.8%进展、25.6%因不良事件停止治疗。
- 6个月和12个月总生存率分别为85.9%(95%CI 76-97)和78.7%(95%CI 67-92)。
关键数值与推荐
- 主要终点阈值:6个月PFS≤50%即判定为无获益(无效假设)。
- 治疗期间平均肿瘤生长速率0.8 mm/月(95%CI -0.2-1.88),治疗前为3.78 mm/月(95%CI 2.61-4.95),p<0.02。
- 疗效与年龄、性别、组织学或基因改变无关。
临床怎么用
- buparlisib单药不作为放射性碘难治性FTC/PDTC的推荐治疗选择。
- 用药期间需重点监测肝炎、高血糖、情绪障碍和皮肤毒性,3-4级不良事件发生率63%。
- 出现严重不良事件时可通过暂时或永久停药或减量处理,原文报告转归良好。
局限性
- 部分分子检测结果仅在部分肿瘤中可获得(RAS 27例、PI3K通路23例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dysregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is frequent in advanced follicular (FTC) and poorly differentiated thyroid (PDTC) carcinomas and has been implicated in oncogenesis and tumor progression. This study investigated the efficacy and safety of buparlisib, a pan-PI3K inhibitor in radioiodine refractory FTC and PDTC. METHODS: The primary endpoint of this open-label, multicenter, phase 2 pilot study was progression-free survival (PFS) at 6 months. The sample size was determined considering that a PFS ≤50% at 6 months would denote an absence of benefits (null hypothesis). Secondary endpoints were objective response rate, PFS at 12 months, overall survival at 6 and 12 months, and safety based on the frequency and severity of adverse events (AEs). RESULTS: Forty-three patients (19M/24 F; median age: 67 years) with metastatic, radioiodine refractory, progressive disease received buparlisib, 100 mg, daily. Histology was PDTC in 25 (58%), FTC in 17 (40%), and Hürthle cell carcinoma in 1 (2%). RAS mutation was found in 44% (12/27) and activation of the PI3K pathway in 35% (8/23) of tested tumors. The probability of PFS was 41.7% [95% confidence interval (CI) 7.7-55.5] at 6 months and 20.9% [CI 0-35.7] at 12 months, lower than the 50% expected PFS. At 6 months, 25.6% patients had stable disease, 48.8% were progressive and 25.6% had stopped treatment due to AE. The response to therapy was not influenced by age, sex, histology, or genetic alterations. The overall survivals at 6 and 12 months were 85.9% [CI 76-97] and 78.7 % [CI 67-92], respectively. The mean tumor growth rate decreased from 3.78 mm/month [CI 2.61-4.95] before treatment to 0.8 mm/month [CI -0.2-1.88] during treatment (p < 0.02). Severe grade 3-4 AEs occurred in 27 patients (63%), including hepatitis (25%), hyperglycemia (21%), mood disorders (12%), and skin toxicity (12%), with favorable outcome after temporary or permanent treatment discontinuation or dose reduction. CONCLUSIONS: Buparlisib did not result in significant efficacy in advanced FTC and PDTC. However, the decrease in tumor growth rate may suggest incomplete inhibition of oncogenic pathways and/or escape mechanisms. This should lead to evaluate combined therapy associating inhibitors of both the PI3K and mitogen-activated protein kinase pathways.
引用
- Borson-Chazot F, Dantony E, Illouz F, et al. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer. Thyroid. 2018. PMID: 30105951. doi:10.1089/thy.2017.0663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。